gemifloxacin_mesylate: profile and news

Oscient Pharmaceuticals Reports Financial Results for First ...  May 9, 2006
In the first quarter of 2006, $9.2 million in revenue was generated from the Company's lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, FDA-approved ... - Genetic Engineering News,

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Apr 20, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News,